ClassID:

96935

C07K14/4747 - CPC Classification

Classification description:

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used Apoptosis related proteins

Recent Application in this class:
#1
20260146275
2026-05-28

METHODS OF PRODUCING POLYPEPTIDES USING A CELL LINE RESISTANT TO APOPTOSIS

#2
20260124240
2026-05-07

DRUG RESISTANT IMMUNE CELLS

#3
20260098278
2026-04-09

CELLS, TISSUES, ORGANS, AND ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND TOLERANCE

#4
20260027154
2026-01-29

Compositions And Methods For Enhancing Adoptive T Cell Therapeutics

#5
20260026479
2026-01-29

GENETICALLY ENGINEERED MICE MODELS FOR MULTIPLE MYELOMA

#6
20260022149
2026-01-22

APOPTOSIS RESISTANT CELL LINES

#7
20260002141
2026-01-01

METHODS AND COMPOSITIONS FOR SELECTIVELY ELIMINATING CELLS OF INTEREST

#8
20260001929
2026-01-01

INDUCIBLE CASPASES AND METHODS FOR USE

#9
20250352614
2025-11-20

PEPTIDE THERAPEUTICS FOR THE TREATMENT OF CANCER AND USES THEREOF

#10
20250346918
2025-11-13

CELLS, TISSUES, ORGANS, AND ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND TOLERANCE

#11
20250270268
2025-08-28

AMELIORATION AND TREATMENT OF INFARCTION DAMAGE

#12
20250223341
2025-07-10

P97-BASE PROTAC ANTIBODY CONJUGATES AND METHODS OF USE

#13
20250223328
2025-07-10

TRUNCATED DOMINANT NEGATIVE CEBPB AND CEBPD PROTEINS AND METHODS OF USE FOR DECREASING VIABILITY OF NEOPLASTIC CELLS

#14
20250163115
2025-05-22

BCL-W Polypeptides and Mimetics for Treating or Preventing Chemotherapy-Induced Peripheral Neuropathy and Hearing Loss

#15
20250115963
2025-04-10

Nucleic Acids, Methods and Kits for the Diagnosis of DYT6 Primary Torsion Dystonia

#16
20250082757
2025-03-13

POLYMER MOLECULE, MONOMERIC STRUCTURE AND POLYMERIC STRUCTURE COMPRISING SAME

#17
20250082723
2025-03-13

METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF TUMORS

#18
20250042962
2025-02-06

COMPOSITIONS TARGETING APOPTOSIS-ASSOCIATED SPECK-LIKE PROTEIN WITH CASPASE ACTIVATION AND RECRUITMENT DOMAIN (ASC) AND METHODS OF USE

#19
20250027045
2025-01-23

ESTABLISHMENT OF ERYTHROID PRECURSOR CELL LINE CAPABLE OF CONDITIONAL MATURATION USING GENE OVEREXPRESSION

#20
20250009796
2025-01-09

PRO-APOPTOTIC CONSTRUCT AND USE THEREOF

#21
20250001014
2025-01-02

BAG3 COMPOSITIONS AND METHODS

#22
20240398896
2024-12-05

INFLAMMASOME INHIBITION

#23
20240398866
2024-12-05

CELLS EXPRESSING FAS LIGAND AND CFLIP POLYPEPTIDES AND USES THEREOF

#24
20240398804
2024-12-05

METHODS OF TREATING CANCER HAVING AN ACTIVE WNT/BETA-CATENIN PATHWAY

#25
20240366760
2024-11-07

ACTIVATION OF SURVIVIN-SPECIFIC IMMUNE RESPONSES USING DENDRITIC CELL DERIVED EXOSOMES

#26
20240335539
2024-10-10

MODULATION OF BCL-2 TO ENHANCE CHIMERIC ANTIGEN RECEPTOR CANCER IMMUNOTHERAPY EFFICACY

#27
20240317829
2024-09-26

APPLICATION OF APOPTOSIS INHIBITOR 5 (API5) FOR EPITHELIAL RESTITUTION

#28
20240316104
2024-09-26

IMMUNE CELLS ENGINEERED TO PROMOTE THANOTRANSMISSION AND USES THEREOF

#29
20240309060
2024-09-19

POLYPEPTIDE BAX/NPM INHIBITORS

#30
20240298619
2024-09-12

NON-HUMAN ANIMALS HAVING A HUMANIZED PROGRAMMED CELL DEATH 1 GENE

#31
20240294664
2024-09-05

CHIMERIC ANTIGEN RECEPTORS, COMPOSITIONS, AND METHODS

#32
20240285775
2024-08-29

COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS

#33
20240285774
2024-08-29

COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS

#34
20240279295
2024-08-22

Compositions targeting apoptosis-associated speck-like protein with caspase activation and recruitment domain (ASC) and methods of use

#35
20240270802
2024-08-15

Compositions and methods for enhancing adoptive T cell therapeutics

#36
20240262878
2024-08-08

PHOTOACTIVATABLE GASDERMIN PROTEINS

#37
20240239857
2024-07-18

IL-13RALPHA2 TARGETED IMMUNOTOXINS AND METHODS OF USE

#38
20240228565
2024-07-11

AMELIORATION AND TREATMENT OF INFARCTION DAMAGE

#39
20240226164
2024-07-11

HYPOIMMUNOGENIC CELLS COMPRISING ENGINEERED HLA-E OR HLA-G

#40
20240192197
2024-06-13

NOVEL SCREENING SYSTEM FOR DRUG TARGET ANTAGONIST BASED ON CELL LIFE/DEATH PHENOTYPE

#41
20240190944
2024-06-13

MODIFIED CELLS FOR THE PRODUCTION OF A RECOMBINANT PRODUCT OF INTEREST

#42
20240174732
2024-05-30

NUCLEIC ACID MOLECULES ENCODING TRIF AND ADDITIONAL POLYPEPTIDES AND THEIR USE IN TREATING CANCER

#43
20240174729
2024-05-30

HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE

#44
20240165161
2024-05-23

COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICS

#45
20240139343
2024-05-02

INCREASED PACKAGING EFFICIENCY OF VECTOR FOR CARDIAC GENE THERAPY

#46
20240115677
2024-04-11

Cancer Stem Cell Targeted Cancer Vaccines

#47
20240092849
2024-03-21

SELECTIVE MCL-1 BINDING PEPTIDES

#48
20240092840
2024-03-21

VACCINE FORMULATION COMPRISING RECOMBINANT OVERLAPPING PEPTIDES AND NATIVE PROTEINS

#49
20240084322
2024-03-14

CELLS, TISSUES, ORGANS, AND ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND TOLERANCE

#50
20240067689
2024-02-29

INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF

#51
20240067685
2024-02-29

HIDDEN ANTIBIOTICS IN THE HUMAN PROTEOME

#52
20240050567
2024-02-15

MODIFIED IMMUNE EFFECTOR CELL AND USE THEREOF

#53
20230414660
2023-12-28

PD-1 DECOY VARIANTS FOR IMMUNOTHERAPY

#54
20230392166
2023-12-07

ANTI-APOPTOTIC VECTOR AND METHOD OF USING THE SAME

#55
20230374092
2023-11-23

METHODS OF TREATING NEURONAL DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF

#56
20230348553
2023-11-02

INDUCIBLE CASPASES AND METHODS FOR USE

#57
20230330227
2023-10-19

GENE FUSIONS FOR CONTROL OF GENETICALLY MODIFIED CELLS

#58
20230279352
2023-09-07

METHODS FOR GENERATING PRIMARY IMMUNE CELLS

#59
20230265433
2023-08-24

SMAC/Diablo inhibitors useful for treating cancer

#60
20230235000
2023-07-27

TREATMENT OF NEURODEGENERATIVE PROTEINOPATHIES USING FAS APOPTOSIS INHIBITORY MOLECULE (FAIM) OR A FRAGMENT AND/OR A MIMETIC THEREOF

#61
20230227583
2023-07-20

COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS

#62
20230221321
2023-07-13

METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

#63
20230203467
2023-06-29

SERINE PROTEASE MOLECULES AND THERAPIES

#64
20230192789
2023-06-22

STRUCTURALLY-STABILIZED AND HDMX-SELECTIVE P53 PEPTIDES AND USES THEREOF

#65
20230151373
2023-05-18

CHIMERIC POLYPEPTIDE FOR REGULATING IMMUNE CELLS

#66
20230093888
2023-03-30

Compositions and methods for delivery of nucleic acids to cells

#67
20230085308
2023-03-16

Compositions and methods for delivery of nucleic acids to cells

#68
20230077821
2023-03-16

BCL-W Polypeptides and Mimetics for Treating or Preventing Chemotherapy-Induced Peripheral Neuropathy and Hearing Loss

#69
20230043763
2023-02-09

Nucleic acids, methods and kits for the diagnosis of DYT6 primary torsion dystonia

#70
20230032060
2023-02-02

Compositions and methods for delivery of nucleic acids to cells

#71
20230002469
2023-01-05

Inducible caspases and methods for use

#72
20220396606
2022-12-15

ENGINEERED HIGH-AFFINITY HUMAN T CELL RECEPTORS

#73
20220387568
2022-12-08

ASC SPECKS IN CANCER IMMUNOTHERAPY

#74
20220372096
2022-11-24

Interleukin-4 Receptor-Binding Fusion Proteins and Uses Thereof

#75
20220348620
2022-11-03

Engineered Peptide and Peptide Mimetic Compositions and Methods

#76
20220339147
2022-10-27

Method of treating diseases of the visual system

#77
20220324943
2022-10-13

MULTIMERIC PROTEIN DOMAINS FOR MULTIFUNCTIONALITY AND ENHANCED SECRETION OF THERAPEUTIC PROTEINS

#78
20220306768
2022-09-29

REDIRECTING DEATH-INDUCING SIGNAL COMPLEX (DISC) BY MODIFYING DEATH RECEPTOR AGONIST TO INDUCE CELL DEATH FOR CANCER TREATMENT

#79
20220306708
2022-09-29

BIFUNCTIONAL STAPLED POLYPEPTIDES AND USES THEREOF

#80
20220249640
2022-08-11

ANTIBODIES AGAINST PD-1 AND METHODS OF USE THEREOF

#81
20220220174
2022-07-14

BNIP3 PEPTIDES FOR TREATMENT OF REPERFUSION INJURY

#82
20220218752
2022-07-14

LOCKR-MEDIATED RECRUITMENT OF CAR T CELLS

#83
20220204575
2022-06-30

MODULATING SURVIVAL OF THERAPEUTIC CELLS AND METHODS, CELLS AND NUCLEIC ACIDS RELATED THERETO

#84
20220170044
2022-06-02

TRANSPOSON-BASED MODIFICATIONS OF IMMUNE CELLS

#85
20220152100
2022-05-19

METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS

#86
20220145253
2022-05-12

CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS

#87
20220127335
2022-04-28

TETRAMERIC PROTEIN SCAFFOLDS AS NANO-CARRIERS OF THERAPEUTIC PEPTIDES FOR TREATING CANCER AND OTHER DISEASES

#88
20220125905
2022-04-28

MESOTHELIN CARS AND USES THEREOF

#89
20220098260
2022-03-31

BH4 Stabilized Peptides And Uses Thereof

#90
20220062261
2022-03-03

Methods of Regulating Oxidoreductase Activity for Treatment of Inflammation and Age-Related Disorders

#91
20220048965
2022-02-17

INTERLEUKIN-4 RECEPTOR-BINDING FUSION PROTEINS AND USES THEREOF

#92
20220041672
2022-02-10

APOPTOSIS RESISTANT CELL LINES

#93
20210363207
2021-11-25

SELECTIVE MCL-1 BINDING PEPTIDES

#94
20210361742
2021-11-25

PEPTIDE THERAPEUTICS FOR THE TREATMENT OF CANCER AND USES THEREOF

#95
20210317501
2021-10-14

METHODS OF PRODUCING POLYPEPTIDES USING A CELL LINE RESISTANT TO APOPTOSIS

#96
20210309706
2021-10-07

METHOD OF RESPONSE PREDICTION FOR BCL2 FAMILY PROTEIN TARGETING DRUG

#97
20210269505
2021-09-02

TWEAK-receptor agonists for use in combination with immunotherapy of a cancer

#98
20210269504
2021-09-02

PROTEIN-BASED MICELLES FOR THE DELIVERY OF HYDROPHOBIC ACTIVE COMPOUNDS

#99
20210261965
2021-08-26

SMAC/Diablo inhibitors useful for treating cancer

#100
20210246183
2021-08-12

Interleukin-2 fusion proteins and uses thereof

#101
20210179683
2021-06-17

METHOD OF RESPONSE PREDICTION FOR BCL2 FAMILY PROTEIN TARGETING DRUG

#102
20210177907
2021-06-17

ENHANCED RECONSTITUTION AND AUTORECONSTITUTION OF THE HEMATOPOIETIC COMPARTMENT

#103
20210169980
2021-06-10

Autophagy inhibitors

#104
20210148907
2021-05-20

Purification and identification of a protein complex containing b-cell lymphoma protein (BCL10)

#105
20210137811
2021-05-13

TRPV3 agonists for the treatment of skin conditions

#106
20210106578
2021-04-15

Method of treating disorders associated with chronic inflammation

#107
20210093701
2021-04-01

Cancer stem cell targeted cancer vaccines

#108
20210079052
2021-03-18

Analogues of VDAC1-derived peptides

#109
20210040176
2021-02-11

High affinity PD-1 agents and methods of use

#110
20200352899
2020-11-12

Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss

#111
20200338061
2020-10-29

Methods of treating sarcopenia

#112
20200315148
2020-10-08

Method for producing chimeric animal

#113
20200308565
2020-10-01

Serine protease molecules and therapies

#114
20200308545
2020-10-01

CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS

#115
20200291125
2020-09-17

Chimeric antigen receptors, compositions, and methods

#116
20200277629
2020-09-03

Retroviral vectors

#117
20200200737
2020-06-25

PROFILING PEPTIDES AND METHODS FOR SENSITIVITY PROFILING

#118
20200179367
2020-06-11

Method of treating coronavirus

#119
20200179366
2020-06-11

Method of treating viral infections

#120
20200179365
2020-06-11

Method of regulating tumor necrosis factor-alpha (TNF-α) for treating cancers, autoimmune disorders, and other disorders associated with chronic inflammation

#121
20200172597
2020-06-04

ARTIFICIAL ANTIGEN PRESENTING CELLS INCLUDING HLA-E AND HLA-G MOLECULES AND METHODS OF USE

#122
20200101070
2020-04-02

Methods of treating cancer having an active Wnt/β-catenin pathway

#123
20200101060
2020-04-02

Method of treating multiple sclerosis

#124
20200078439
2020-03-12

Powerful MHC-class II peptides derived from survivin

#125
20200078344
2020-03-12

Methods of reversing normal aging process and extending lifespan

#126
20200071419
2020-03-05

ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR

#127
20200061043
2020-02-27

Pharmaceutical salts of isomyosmine and pharmaceutical compositions containing same

#128
20200053992
2020-02-20

Non-human animals having a humanized programmed cell death 1 gene

#129
20200040100
2020-02-06

Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents

#130
20200010821
2020-01-09

Serine protease molecules and therapies

#131
20190375808
2019-12-12

Analogues of VDAC1-derived peptides

#132
20190367573
2019-12-05

p53-BAD fusion proteins

#133
20190336577
2019-11-07

Methods and compositions relating to the treatment of tumors

#134
20190309038
2019-10-10

Engineered potent cytotoxic stapled BH3 peptides

#135
20190256837
2019-08-22

Serine protease molecules and therapies

#136
20190256833
2019-08-22

Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system

#137
20190256615
2019-08-22

Site-selective modification of polysaccharides and applications thereof

#138
20190249172
2019-08-15

METHODS AND COMPOSITIONS FOR GENE EDITING IN STEM CELLS

#139
20190241959
2019-08-08

Nucleic acids, methods and kits for the diagnosis of DYT6 primary torsion dystonia

#140
20190225667
2019-07-25

Inducible caspases and methods for use

#141
20190185531
2019-06-20

Selective Bfl-1 peptides

#142
20190178873
2019-06-13

Profiling peptides and methods for sensitivity profiling

#143
20190161525
2019-05-30

Method for treating Alzheimer's disease and method for downregulating protein aggregation in brain

#144
20190142870
2019-05-16

Enhanced reconstitution and autoreconstitution of the hematopoietic compartment

#145
20190119357
2019-04-25

MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF

#146
20190100568
2019-04-04

Interleukin-4 receptor-binding fusion proteins and uses thereof

#147
20190100567
2019-04-04

Interleukin-4 receptor-binding fusion proteins and uses thereof

#148
20190092822
2019-03-28

BH4 stabilized peptides and uses thereof

#149
20190077840
2019-03-14

SELECTIVE MCL-1 BINDING PEPTIDES

#150
20190055298
2019-02-21

ENGINEERED HIGH-AFFINITY HUMAN T CELL RECEPTORS

#151
20190024070
2019-01-24

REWIRING ABERRANT CANCER SIGNALING TO A THERAPEUTIC EFFECTOR RESPONSE WITH A SYNTHETIC TWO-COMPONENT SYSTEM

#152
20190024051
2019-01-24

Conditionally immortalized long-term stem cells and methods of making and using such cells

#153
20190022225
2019-01-24

PROTOCOL FOR INCREASING LIFE EXPECTANCY IN A TEST SUBJECT

#154
20190016767
2019-01-17

Multimodal trail molecules expressed in T cells

#155
20190002514
2019-01-03

Peptides binding to Bfl-1

#156
20180360004
2018-12-20

Method for producing chimeric animal

#157
20180348219
2018-12-06

ANTI-TNF INDUCED APOPTOSIS (ATIA) DIAGNOSTIC MARKERS AND THERAPIES

#158
20180327470
2018-11-15

Chimeric antigen receptor-modified immune effector cell carrying PD-L1 blocking agent

#159
20180312565
2018-11-01

Polypeptide

#160
20180305702
2018-10-25

Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment

#161
20180299432
2018-10-18

Profiling peptides and methods for sensitivity profiling

#162
20180296703
2018-10-18

BAG3 COMPOSITIONS AND METHODS

#163
20180244740
2018-08-30

BH3 peptides and methods of use thereof

#164
20180206462
2018-07-26

NON-HUMAN ANIMALS HAVING A HUMANIZED PROGRAMMED CELL DEATH 1 GENE

#165
20180201918
2018-07-19

Serine protease molecules and therapies

#166
20180193458
2018-07-12

COMPOSITIONS AND METHODS FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS

#167
20180172673
2018-06-21

Profiling peptides and methods for sensitivity profiling

#168
20180134760
2018-05-17

Analogues of VDAC1-derived peptides

#169
20180127470
2018-05-10

Cell Lines

#170
20180117089
2018-05-03

Enhanced reconstitution and autoreconstitution of the hematopoietic compartment

#171
20180100001
2018-04-12

BIFUNCTIONAL STAPLED POLYPEPTIDES AND USES THEREOF

#172
20180085296
2018-03-29

TRPV3 agonists for the treatment of skin conditions

#173
20180042909
2018-02-15

Methods of treating diabetes

#174
20180038874
2018-02-08

13+/17+ BIN1 expression as a marker of cardiac disorders

#175
20180030109
2018-02-01

Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide, methods and uses therefor

#176
20180021321
2018-01-25

Methods of altering programmed cell death and extending cell life

#177
20180015152
2018-01-18

Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway

#178
20180015137
2018-01-18

Anti-senescence compounds and uses thereof

#179
20180009864
2018-01-11

Synthetic promoters for high throughput screening and gene modulation

#180
20180002438
2018-01-04

Chimeric antigen receptors, compositions, and methods

#181
20180000912
2018-01-04

Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity

#182
20170362580
2017-12-21

METHODS AND COMPOSITIONS FOR SELECTIVELY ELIMINATING CELLS OF INTEREST

#183
20170327592
2017-11-16

Polypeptide immunogen for generating an antibody to non-functional P2X7 receptor

#184
20170319670
2017-11-09

MHC-I restricted epitopes containing non-natural amino acid residues

#185
20170299576
2017-10-19

PEPTIDOMIMETIC MACROCYCLES

#186
20170298108
2017-10-19

Compositions comprising GRIM-19 therapeutics and methods of use

#187
20170296620
2017-10-19

Bis-sulfhydryl macrocyclization systems

#188
20170276681
2017-09-28

Methods and compositions for diagnosis and treatment of cancer

#189
20170274046
2017-09-28

COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEUROLOGICAL DISEASE

#190
20170233451
2017-08-17

High affinity PD-1 agents and methods of use

#191
20170226170
2017-08-10

Calbindin and BH3 domain chimeric proteins and methods for use

#192
20170174734
2017-06-22

DR6 Receptor Mediates the Leukemia Differentiation Activity of Angiocidin: A Potent Anti-Tumor Peptide

#193
20170151345
2017-06-01

Methods for treating cancer with EGFR nanobodies linked to DR5 binding moieties

#194
20170096500
2017-04-06

Site-selective modification of polysaccharides and applications thereof

#195
20170081380
2017-03-23

Method of treating BCL-2 over-expressing disorders using arts containing a BH3-like domain

#196
20170066799
2017-03-09

Stitched polypeptides

#197
20170058010
2017-03-02

Methods and pharmaceutical compositions for the treatment of cancer

#198
20170044226
2017-02-16

Membrane-anchoring and apoptosis-inducing fusion protein comprising a fragment of TRAIL and CD40L and encoding polynucleotides

#199
20170037154
2017-02-09

Composition comprising branched multipeptide vaccine and vaccine comprising the same

#200
20170022263
2017-01-26

Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide, methods and uses therefor

#201
20170016898
2017-01-19

Cell-surface marker of early MSC aging

#202
20170015718
2017-01-19

PRO-APOPTOTIC RAS AND RAF PEPTIDES

#203
20170009252
2017-01-12

Vectors and methods for the efficient generation of integration/transgene-free induced pluripotent stem cells from peripheral blood cells

#204
20170008930
2017-01-12

STABILIZED ALPHA HELICAL PEPTIDES AND USES THEREOF

#205
20160377633
2016-12-29

Bcl-2-like protein 11 SRM/MRM assay

#206
20160376336
2016-12-29

Engineered potent cytotoxic stapled BH3 peptides

#207
20160376333
2016-12-29

Polypeptides to inhibit epstein barr viral protein BHRF1 and B cell lymphoma family proteins

#208
20160376307
2016-12-29

IAP antagonists

#209
20160355785
2016-12-08

Expansion of adult stem cells in vitro

#210
20160333064
2016-11-17

Biodegradable matrix comprising stem cells that express soluble TRAIL

#211
20160280756
2016-09-29

Engineered high-affinity human t cell receptors

#212
20160280755
2016-09-29

Engineered high-affinity human T cell receptors

#213
20160279213
2016-09-29

Survivin-Directed Cancer Vaccine Therapy

#214
20160272691
2016-09-22

COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH y-HERPESVIRUSES

#215
20160257713
2016-09-08

Cell-penetrating peptides

#216
20160237135
2016-08-18

Interleukin-4 receptor-binding fusion proteins and uses thereof

#217
20160229901
2016-08-11

Interleukin-2 fusion proteins and uses thereof

#218
20160222454
2016-08-04

Nucleic acids, methods and kits for the diagnosis of DYT6 primary torsion dystonia

#219
20160215035
2016-07-28

Interleukin-4 receptor-binding fusion proteins and uses thereof

#220
20160200786
2016-07-14

BH3 peptides and methods of use thereof

#221
20160193314
2016-07-07

Uses of partial peptides of survivin and variations thereof

#222
20160186196
2016-06-30

METHOD AND COMPOSITION FOR GENERATING PROGRAMMED CELL DEATH RESISTANT ALGAL CELLS

#223
20160176938
2016-06-23

Partial region polypeptide of REIC/Dkk-3 protein

#224
20160176937
2016-06-23

Short peptides derived from VDAC1, compositions and methods of use thereof

#225
20160168227
2016-06-16

COMPOSITION AND VACCINE FOR TREATING LUNG CANCER

#226
20160145308
2016-05-26

Compositions and methods for targeted endometriosis treatment

#227
20160122730
2016-05-05

Molecules of the card-related protein family and uses thereof

#228
20160122413
2016-05-05

Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein

#229
20160108100
2016-04-21

Interference peptides and use thereof

#230
20160101171
2016-04-14

MELK epitope peptides and vaccines containing the same

#231
20160096881
2016-04-07

Means and methods for producing high affinity antibodies

#232
20160096873
2016-04-07

PEPTIDOMIMETIC MACROCYCLES

#233
20160095896
2016-04-07

Bis-sulfhydryl macrocyclization systems

#234
20160073616
2016-03-17

METHOD FOR PRODUCING CHIMERIC ANIMAL

#235
20160050894
2016-02-25

Maternally induced sterility in animals

#236
20160031959
2016-02-04

BH4 stabilized peptides and uses thereof

#237
20160024164
2016-01-28

CHEMOTHERAPEUTIC AGENTS COMPRISING A CHIMERIC GENE, METHODS OF PRODUCING THE SAME, AND METHODS OF TREATING CANCEROUS CELLS USING THE SAME

#238
20160022787
2016-01-28

MHC-I restricted epitopes containing non-natural amino acid residues

#239
20150366174
2015-12-24

Non-human animals having a humanized programmed cell death 1 gene

#240
20150359840
2015-12-17

Autophagy-inducing peptide analogs

#241
20150344525
2015-12-03

Dual-targeted therapeutic peptide for nasopharyngeal carcinoma, nanoparticles carrying same and uses thereof

#242
20150274839
2015-10-01

Antibodies to non-functional P2X7 receptor

#243
20150266968
2015-09-24

Polypeptides capable of cellular internalization

#244
20150265693
2015-09-24

Therapeutic agent for cancer

#245
20150246955
2015-09-03

Methods and compositions for specific modulation of MCL-1

#246
20150240205
2015-08-27

Conditionally immortalized long-term stem cells and methods of making and using such cells

#247
20150233943
2015-08-20

BLID; protein domain for interaction with the Bcl-2 family of proteins

#248
20150218282
2015-08-06

Multifunctional nanobodies for treating cancer

#249
20150164950
2015-06-18

Enhanced reconstitution and autoreconstitution of the hematopoietic compartment

#250
20150141627
2015-05-21

Method for antigen delivery

#251
20150139939
2015-05-21

Cancer stem cell targeted cancer vaccines

#252
20150125491
2015-05-07

Immunomodulating cyclic compounds

#253
20150105286
2015-04-16

BLID; a novel protein domain for interaction with the Bcl-2 family of proteins. Applications in oncology

#254
20150094268
2015-04-02

Prophylactic or therapeutic agent for hepatic diseases

#255
20150065518
2015-03-05

Methods of treating cancer having an active Wnt/β-catenin pathway

#256
20150050304
2015-02-19

CD4+ T survivin epitopes and uses thereof

#257
20150045310
2015-02-12

Engineered potent cytotoxic stapled BH3 peptides

#258
20150045308
2015-02-12

Compositions and methods of treating cancer

#259
20150030699
2015-01-29

Anti-tumor adjuvant therapy

#260
20150018285
2015-01-15

ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS

#261
20150010556
2015-01-08

Serine protease molecules and therapies

#262
20140364376
2014-12-11

Cell-penetrating peptides

#263
20140349344
2014-11-27

Compositions and methods for purifying Bax

#264
20140342994
2014-11-20

Fusion protein comprising circularly permuted form of trail/Apo2L, coding gene and use thereof

#265
20140342993
2014-11-20

Kinase inhibitors and uses thereof

#266
20140314760
2014-10-23

Serine protease molecules and therapies

#267
20140302502
2014-10-09

Bin1 as a prognostic marker in cardiovascular disease

#268
20140296160
2014-10-02

Stabilized alpha helical peptides and uses thereof

#269
20140288006
2014-09-25

PTD-SMAD7 therapeutics

#270
20140227767
2014-08-14

PEPTIDES AND METHODS FOR INDUCING CELL DEATH

#271
20140155330
2014-06-05

Compositions And Methods For Modulating Apoptosis

#272
20140141028
2014-05-22

Melk epitope peptides and vaccines containing the same

#273
20140140976
2014-05-22

Serine protease molecules and therapies

#274
20140135473
2014-05-15

Bis-sulfhydryl macrocyclization systems

#275
20140127736
2014-05-08

Annexin V variant and its preparation and application

#276
20140127242
2014-05-08

Powerful MHC-class II peptides derived from survivin

#277
20140086924
2014-03-27

Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins

#278
20140086907
2014-03-27

Treatment and bioluminescent visualization using multimodal TRAIL molecules

#279
20140066382
2014-03-06

Autophagy-inducing peptide

#280
20140065695
2014-03-06

PEPTIDES AND METHODS FOR INDUCING CELL DEATH

#281
20140057857
2014-02-27

Cross-linked peptides and proteins, methods of making same, and uses thereof

#282
20140050749
2014-02-20

MHC-I restricted epitopes containing non-natural amino acid residues

#283
20130331552
2013-12-12

Means and methods for producing high affinity antibodies

#284
20130323752
2013-12-05

BLID; a novel protein domain for interaction with the Bcl-2 family of proteins

#285
20130323272
2013-12-05

Powerful MHC-class II peptides derived from survivin

#286
20130316958
2013-11-28

HIGHLY POTENT PEPTIDES TO CONTROL CANCER AND NEURODEGENERATIVE DISEASES

#287
20130302334
2013-11-14

BCL-2-like protein 11 SRM/MRM assay

#288
20130302270
2013-11-14

Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same

#289
20130288979
2013-10-31

Inhibitors of apoptosis and uses thereof

#290
20130288963
2013-10-31

Anticancer fusion protein comprising trail and a growth factor receptor inhibitor

#291
20130280268
2013-10-24

Oxidative stress responsive apoptosis inducing protein eIF5A

#292
20130274199
2013-10-17

Direct administration of REIC/Dkk-3 to mesothelioma

#293
20130217633
2013-08-22

Inhibitors of Bcl-2

#294
20130202678
2013-08-08

Puf-A and related compounds for treatment of retinopathies and sight-threatening ophthalmologic disorders

#295
20130196922
2013-08-01

BNIP3 ISOFORMS AND METHODS OF USE

#296
20130184221
2013-07-18

Kinase inhibitors and uses thereof

#297
20130164254
2013-06-27

Anticancer fusion protein comprising trail

#298
20130129736
2013-05-23

ASPP2 splicing variant

#299
20130115216
2013-05-09

Survivin-derived peptides and uses thereof

#300
20130065312
2013-03-14

METHOD AND COMPOSITION FOR GENERATING PROGRAMMED CELL DEATH RESISTANT ALGAL CELLS